The latest announcement is out from Tarsus Pharmaceuticals ( (TARS) ).
Tarsus Pharmaceuticals appointed Elizabeth Yeu, M.D. as Chief Medical Officer, effective November 4, 2024. Dr. Yeu, a prominent figure in ophthalmology, resigns from the board to focus on her new role. Her compensation package includes a base salary, bonuses, and stock options. The agreement also outlines severance and change in control benefits, ensuring security in her position. This strategic move highlights the company’s commitment to advancing its medical leadership.
For a thorough assessment of TARS stock, go to TipRanks’ Stock Analysis page.
